To tweak CAR-T therapies for myeloma, researchers are trying to repurpose a failed Alzheimer’s drug and are extracting patients’ T cells sooner.
Patients who received intensification treatment experienced longer progression-free survival compared with patients receiving maintenance treatment.
Patients receiving the 3-drug treatment experienced increasing rates of complete response and measurable residual disease from induction through consolidation.
Progression-free survival significantly longer with lenalidomide compared with observation
A hematologic score based on specific blood parameters was evaluated for its potential to predict survival in patients with newly diagnosed multiple myeloma.
Increased hospital activity unrelated to hematology seen for years before diagnosis
Time to initiation of therapy was significantly longer for black and Hispanic patients compared with white patients.
A new study aims to address the conundrum of coagulation risk in patients hospitalized for hematologic malignancies.
Prolonged closure time and defects in von Willebrand factor were identified as risk factors for bleeding complications patients with multiple myeloma.
Researchers conducted a subgroup analysis of Asian patients with relapsed or refractory multiple myeloma who received carfilzomib in 2 phase 3 clinical trials.
A critical step in the preparation of autologous CAR-T therapy is the ex vivo proliferation of T cells from samples obtained from leukapheresis.
In this systematic review, researchers analyzed the cost effectiveness of various treatments and treatment lines for multiple myeloma.
A case series study demonstrated the importance of timely, preventive dental assessment for patients with multiple myeloma.
Patients who were treated with carfilzomib, dexamethasone, and daratumumab had not reached median progression-free survival at the cutoff date.
An analysis of completion rates for PRO measures among patients with multiple myeloma found that reminders and use of preferred delivery mode influence response rate.
Advances in technology for detecting measurable residual disease (MRD) are also raising questions regarding the role of MRD in managing multiple myeloma.
A new risk stratification score for venous thromboembolism was developed and validated in a cohort of more than 4000 patients with multiple myeloma.
A retrospective cohort study identified real-world epidemiology, treatment patterns, and survival outcomes in patients with multiple myeloma in Israel.
Irreversible proteasome inhibitor carfilzomib appears to cause reticulocytosis in multiple myeloma by inhibiting terminal erythroid maturation.
Patients who received autologous transplant followed by allogeneic transplant experienced improved progression-free survival.
Results of a phase 1/2 trial demonstrated the efficacy of nelfinavir in combination with lenalidomide and dexamethasone for lenalidomide-refractory MM.
Plitidepsin plus dexamethasone yielded improved progression-free and overall survival compared with dexamethasone alone.
Factors associated with poor adherence to specific guideline-recommended supportive care measures involved patient race and site of care.
A tumor-initiating cell marker was identified in multiple myeloma cell lines and patient samples; evidence suggests the marker may have therapeutic potential.
All-oral regimen linked to higher satisfaction with treatment convenience in relapsed, refractory MM
Cardiovascular adverse events were more common with carfilzomib therapy and within the first 3 months of treatment.
For patients receiving drug therapy, economic burden substantial across lines of therapy
Two randomized phase 3 trials investigating the safety and efficacy of adding pembrolizumab to standard-of-care therapies for multiple myeloma were halted due to poor outcomes in their respective intervention arms.
Retrospective population-based cohort study is used to validate a new risk assessment tool to identify patients receiving immunomodulatory drugs for multiple myeloma who may be at high risk of VTE.
Progressive MGUS and light-chain MGUS were both associated with skewed serum free light chain ratios.
Oncologists are changing the way they treat, perhaps too quickly and with too little evidence — but the behavior may signal a bigger problem with how research is reported.
Very good partial response or better was seen in nearly two-thirds of patients receiving the triplet treatment.
Patients who were naive to daratumumab experienced an overall response rate of 91.7%; median progression-free survival in this cohort was not reached.
Continued approval of Xpovio for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
The FDA has expanded the approval of Darzalex (daratumumab; Janssen Biotech) to include use in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Median overall survival was 3.6 years for patients who received upfront therapy and 4.2 years for patients who did not.
The rate of infusion reactions was substantially lower in patients receiving SC compared with intravenous daratumumab.
Pomalidomide-based triplet therapies appear safe, effective, and associated with improved outcomes compared with the current standard of care.
Lenalidomide reduced the risk of disease progression in patients with intermediate- or high-risk smoldering multiple myeloma, but discontinuation rates were high.
Patients receiving daratumumab demonstrated a statistically significant decline in pain symptoms that was sustained over time.
When added to bortezomib, thalidomide, and dexamethasone, daratumumab was associated with higher rates of measurable disease negativity.
Patients with both high and standard cytogenetic risk who received daratumumab experienced increased PFS.
Carfilzomib administered once weekly demonstrated benefit in progress-free survival independent of patient frailty.
Researchers developed a new model for risk stratification in patients with SMM based on updated criteria.
Median progression-free survival was 22.3 months in patients receiving carfilzomib and 22.1 months in patients receiving bortezomib.
Identifying patients with smoldering myeloma at high risk for disease progression may allow for implementation of better treatment strategies.
Busulfan plus melphalan may be a viable pretreatment conditioning regimen for patients undergoing autologous hematopoietic stem cell transplantation.
Proteasome inhibitors and immunomodulatory drugs have demonstrated improvements in survival and response in patients with multiple myeloma.
Twitter is increasingly being used by oncologists as a tool to communicate advancements in in the treatment of cancer. What could go wrong?
Translocations of IgL occurred in approximately 10% of patients with newly diagnosed multiple myeloma.
Pomalidomide, cyclophosphamide, and dexamethasone triplet therapy for relapsed/refractory multiple myeloma had an overall response rate of 76%.